Non CME Events

Monday, October 22
6:30 pm – 10:30 pm

A Multidisciplinary Approach to Personalizing Medicine for Non-small Cell Lung Cancer
Over the past decade, clinically relevant biomarkers have been identified in non-small cell lung cancer (NSCLC). Individualizing treatment for NSCLC based on molecular markers involves routine biomarker testing that requires efficient, coordinated efforts and continued communications across multiple specialists, including pulmonologists, pathologists, and medical oncologists. This non-CME symposium will delve into a multidisciplinary team approach, emphasizing the critical role of the pulmonologist and exploring testing and subsequent personalized treatment plans for patients with advanced NSCLC.
Supported by Boehringer-Ingelheim Pharmaceuticals.

Reducing the Risk of Exacerbations of COPD: Proactively Managing Patients at Risk and Optimizing Care for Hospitalized Patients
This symposium will explore the relevance of proactively managing patients with COPD at risk for exacerbations, potentially minimizing future office visits and hospitalizations. Topics will include strategies for reducing the exacerbation risk and approaches to the transition of patients from the hospital following an acute exacerbation.
Only health-care providers who treat COPD are eligible to participate in this non-CME educational program, sponsored by Forest Pharmaceuticals, Inc. Due to legal restrictions in some states, dinner may not be available to all participants at this industry-organized symposium at CHEST 2012.
Supported by Forest Pharmaceuticals, Inc.

Controversies in PAH Part II: Exploring Patient Co-Management
Faculty
Victor Tapson, MD, FCCP, Durham, NC
Hunter Champion, MD, PhD, Pittsburgh, PA
Ioana Preston, MD, Boston, Massachusetts
Aryeh Fischer, MD, Denver, CO
Amgad Abdu, MD, Franklin, PA
Controversies in PAH Part II: Exploring Patient Co-Management is a non-CME dinner symposium offered to CHEST registrants. Leading experts in pulmonary arterial hypertension will explore compelling questions in the comanagement of PAH patients, from the perspectives of the pulmonary hypertension center, rheumatologist, and community-based physician. Join us for discussions on a series of new patient case studies and multidisciplinary approaches to this difficult disease.
Supported by Gilead Sciences Inc.

Tuesday, October 23
6:00 pm – 10:00 pm

Perspectives in PAH: The Evolution of Clinical Trial Design and Clinical Practice
The science of pulmonary arterial hypertension (PAH) has advanced significantly over the past decade. During this symposium, a panel of experts will discuss how these developments influence not only our thinking about the disease itself but also the evolution of clinical trial design and PAH management in clinical practice.
Dinner will be provided. Dinner will not be provided to physicians and other health-care professionals licensed in Vermont or other states where gifts and meals are prohibited.
Supported by Actelion Pharmaceuticals US, Inc.

Wednesday, October 24
5:30 am – 7:30 am

Improving Lung Function in COPD Patients: A Treatment Update
Supported by Forest Pharmaceuticals, Inc.

New Horizons in Pulmonary Arterial Hypertension: The Future Is Now
The diagnosis and management of pulmonary arterial hypertension (PAH) has changed dramatically over the past 2 decades. Despite advances in PAH therapy, the disease continues to be progressive and often fatal. Thus, the quest for safe and more effective therapies continues. New Horizons in Pulmonary Arterial Hypertension: The Future Is Now will provide clinicians with the state-of-the-art overview of the available treatments and review new and exciting developments in the management of PAH that may soon be available to further optimize their patients’ care.
Supported by Foundation for Medical Education and Research.